SAPHIRe
Securing Adoption
of Personalised
Health in Regions

The personalised future of healthcare in Europe

Identifying the regional roadblocks for the implementation of personalised health

Introduction



Personalised medicine - Definition


"A medical model using characterization of individuals' phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"

- H2020 Advisory group and Council conclusion 2015/C 421/03 (7-12-2015)



Personalised medicine

Healthcare shift from symptomatic treatment towards ensuring lifelong health



Profound understanding of health, disease, aging



- Early, accurate diagnosis
- Increase healthy life years
- Sustainability of healthcare
- Boost development of new technologies, treatments & therapies



SAPHIRe

Securing the Adoption of Personalised Health in Regions

Aim - Support European regions to structure implementation of personalised medicine

Scout ► Map specific regional gaps and barriers, incl. from remote and sparsely populated regions

Connect ► Create network of stakeholders, to bring regional strengths, needs & barriers to attention of national/EU policy makers

Activate ► Enable inter-regional collaborations

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825046

Partners













Regional networking

Bring together


- Central & densely populated regions
- Remote & sparsely populated regions
- Different innovation levels

Identify

- Gaps & barriers
- Best practices
- Regional value chains
- Complementarities between regions

Link to

- ICPerMed
- Smart specialisation <u>S3P4PM</u>




http://ec.europa.eu/growth/industry/innovation/facts-figures/regional_en



Workshop: regional needs and barriers



Participating regions and countries



| Regions represented |
|---------------------------------|
| Oulu (FI) |
| Zealand (DK) |
| Capital Region (DK) |
| Podlanskie (PL) |
| Schotland (UK) |
| Northern Ireland (UK) |
| Flanders (BE) |
| Nord-Est (RO) |
| Provence-Alpes-Côte d'Azur (FR) |
| Lombardy (IT) |
| Piedmont (IT) |
| Campania (IT) |
| Extremadura (ES) |
| Countries represented |
| Sweden |
| Hungary |
| Slovenia |
| Greece |
| Portugal |



Participants ranked interference of possible barriers prior to workshop

ICPerMed Challenges

- Awareness and empowerment
- Integration of big data and digital solutions
- Translating basic research to clinical research
- Bringing innovation to market
- Sustainability of healthcare

Data-related challenges

- Availability of data
- Fragmentation of data
- Privacy issues
- Impact of GDPR guidelines

Policy challenges

- Fragmentation of authority level within and between regions
- Availability and access to funding



13/45 (29%) of invitees completed the questionnaire






Challenges identified during the workshop

- 1. Data
- 2. Logistics and infrastrucure
- 3. Awareness and empowerment
- 4. Bringing innovation to market
- 5. Skills of the future
- 6. Policy
- 7. Remote and sparsely populated regions




1. Data

Large scale integration of big data will create opportunities to improve healthcare




1. Data

Large scale integration of big data will create opportunities to improve healthcare



2. Logistics and infrastructure

Servers will have to store several petabytes of information




2. Logistics and infrastructure


Improve manufacturing in order to upscale personalised medicine

NFFDS

Create protocols

- Optimise transport of cells and tissues
- Standardise procedures
- Automation of procedures
- Make standards interoperable
 Regional → National ← European level
- Create biobanks containing personal tissues
 & cells









Cells are tested for safety and potency and

packaged for injection back into the patient.

CELL EXPANSION AND HARVES

Genetically modified cells are cultured to **produce enough new cells** for a therapeutic dose. **CELL MODIFICATION**

Immune cells are



3. Awareness and empowerment

Empower all stakeholders to support personalised medicine

Secure **trust**: create digital ethics and privacy regulation




Support research: provide access to lifestyle and genomic data



Policy makers

Adopt advanced technologies: provide better healthcare






Adapt curriculum to develop **novel** skill sets and jobs of the future



Clear science communication: showcase advanced therapies & technologies

4. Bringing innovation to market

Translate results from basic research to market entrance



Public

procurement

Needs from healthcare

providers, patients, public, ...

Close collaboration

between beneficiaries



4. Bringing innovation to market

Health system payers need evidence that therapy/test gives <u>clinical added-value</u> before making reimbursement decisions

BARRIERS

- Regulatory evidence for reimbursements ≠ standardised
- Healthcare in Europe = fragmented (control @ regional ↔ @ national level)
- No strategy for preventive medicine

NEEDS

- Dialogue between regions & countries:
 - Create common vision in Europe towards industry
- Increase predictability of reimbursements \rightarrow create incentive for investing in PM
- Role of regulatory offices





5. Skills of the future

Innovation in personalised medicine needs novel skill base and knowledge sets

Training of young professionals Lifelong learning Healthcare professionals Cross-disciplinary Clinical geneticists & Digital health & care genetic counselors IT specialists programmes **Biomedical** Data science & researchers stewardship Implementation of digital technologies



6. Policy

Creation of a strong regulatory framework

Uniformity within European regions will

- Promote interregional collaboration & data sharing
- Provide safe governance of personal data
- Ensure quality of data
- Create trust between stakeholders

Who can collect data? Who can access data? For what purpose? Opportunities GDPR vs **CLOUD Act?**

Collect input from













Scientific experts Policy makers Ethical specialists Social scientists



7. Remote and sparsely populated regions

Remote regions may face additional barriers related to their less centralised location



Long distances to medical doctor/hospital



Lack of specialised healthcare professionals

eHealth and telemedicine



Unique genetic background & founder mutations

Location-specific treatments

Location-specific carrier screening



Overview of implications



1. Data

- Share data within and between regions
- Extract data for reuse and re-analysis
- Implementation of artificial intelligence
- · No standardisation
- · Lack of integration

- 2. Logistics & infrastructure
- Infrastructure for the storage of big data
- (Manufacturing) protocols to upscale PM
- Storage costs for big data
- No standardisation of procedures

- 3. Awareness & empowerment
- Longitudinal- & societal-based learning environment
- New skill base & knowledge set

More active

healthcare

professionals

involvement of

patients & citizens

Lack of awareness

- 4. Bring innovation to market
- Better transition from basic research > clinical trials > market

Gap between

& industry

in Europe

academics, clinicians

· Fragmentation of

healthcare systems

5. Policy

- Strong regulatory framework at European scale
- Evidence base for PM
- Who can collect and access data? For what purpose?

Securing the Adoption of Personalised Health in Regions

- Create data standards and agree on semantics
- Make data FAIR
- Create user-friendly user interfaces for databases
- Investments and funding
- Education: skills of the future (data scientists and data stewards, ...) + training of MDs

- Investments in infrastructure and standardisation
- Creation of servers and biobanks
- Standardise (manufacturing) procedures
- Showcase benefits of EU standards
- Create frameworks to make regional standards

interoperable

- Include citizens/patient (organisations) in policy making
- Showcase regional success stories
- Education: curricula to prepare for the skills of the future (medical geneticists, genetic counsellors, ...)

- Funding & investments
- Co-creation projects
- Protective time for research
- Disseminate results to general public
- Robust evidence base for PM
- Increased collaboration between regions related to medical

reimbursements

- Get input from all stakeholders to create regulatory framework, incl. ethicists and social scientists
- Robust evidence base for PM

SAPHIRe
Securing Adoption
of Personalised
Health in Regions

www.saphire-eu.eu
info@saphire-eu.eu

@projectSAPHIRe

Creative commons licenses

- Slide 8: Image modified under a Creative Commons CC-BY-SA2.5, source: https://commons.wikimedia.org/wiki/File:NUTS_2_regions_EU-27.svg. The destination icon is licensed as Creative Commons CC-BY: destination by Daniel Falk from the Noun Project.
- Slide 15: https://www.imec-int.com/cache/pdfs/en/imec-magazine/imec-magazine-february-2018/what-chip-technology-can-do-for-cell-therapy.pdf
- Following icons were licensed as Creative Commons CC-BY:
 - DNA by Adib Muhammad from the Noun Project
 - yoga by priyanka from the Noun Project
 - Server by Eucalyp from the Noun Project
 - Doctor by priyanka from the Noun Project
 - avatar by Creative Stall from the Noun Project
 - Programmer by Chameleon Design from the Noun Project
 - Science by Chameleon Design from the Noun Project
 - women by Delwar Hossain from the Noun Project
 - Question by Sergey Novosyolov from the Noun Project
 - contract by Giuditta Valentina Gentile from the Noun Project
 - collaboration by Chanut is Industries from the Noun Project
 - Question by i cons from the Noun Project
 - thinker by Gilbert Bages from the Noun Project
 - psychology by Gilbert Bages from the Noun Project
 - distance by Fahmihorizon from the Noun Project
 - payment by Gregor Cresnar from the Noun Project

